Literature DB >> 2088644

Apheresis enhances the selective removal of antinuclear antibodies in systemic lupus erythematosus.

K K Colburn1, G A Gusewitch, B S Statian Pooprasert, R H Weisbart.   

Abstract

Apheresis suppresses clinical manifestations of lupus and reduces levels of antinuclear antibodies implicated in the pathogenesis of systemic lupus erythematosus (SLE). It is not known, however, if reduced levels of antinuclear antibodies are due to nonspecific removal, or specific mechanisms associated with decreased production, or enhanced clearance from the circulation. In order to distinguish between specific and nonspecific effects of apheresis on antinuclear antibodies in SLE, we compared plasma levels of IgG antibodies to DNA and IgG antibodies to microbial antigens in 13 SLE patients before and after apheresis. Although apheresis lowered plasma levels of IgG (21% mean reduction), there was a disproportionate reduction in IgG antibodies to DNA (42% mean reduction, p less than 0.13). In marked contrast, reduction in antibodies to microbial antigens did not exceed those of plasma IgG. A rapid rebound of serum anti-DNA antibodies following apheresis in certain SLE patients suggests that the selective reduction in anti-DNA antibodies is due to enhanced clearance from the circulation rather than decreased production. These results indicate that apheresis enhances selective removal of antinuclear antibodies in some patients with SLE.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2088644     DOI: 10.1007/BF02030508

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  25 in total

1.  ANTIBODIES SPECIFIC FOR RIBONUCLEOSIDES AND RIBONUCLEOTIDES AND THEIR REACTION WITH DNA.

Authors:  B F ERLANGER; S M BEISER
Journal:  Proc Natl Acad Sci U S A       Date:  1964-07       Impact factor: 11.205

2.  Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus.

Authors:  J O Schroeder; H H Euler; H Löffler
Journal:  Ann Intern Med       Date:  1987-09       Impact factor: 25.391

3.  Randomised trial of plasma exchange in mild systemic lupus erythematosus.

Authors:  N Wei; J H Klippel; D P Huston; R P Hall; T J Lawley; J E Balow; A D Steinberg; J L Decker
Journal:  Lancet       Date:  1983-01-01       Impact factor: 79.321

4.  Plasmapheresis in systemic lupus erythematosus: a cautionary note.

Authors:  R Schlansky; R J DeHoratius; T Pincus; K S Tung
Journal:  Arthritis Rheum       Date:  1981-01

Review 5.  The role of therapeutic plasmapheresis in the rheumatic diseases.

Authors:  J V Jones; J D Clough; J R Klinenberg; P Davis
Journal:  J Lab Clin Med       Date:  1981-05

6.  Plasmapheresis in active systemic lupus erythematosus: effects on clinical, serum, and cellular abnormalities. Case report.

Authors:  N I Abdou; H B Lindsley; A Pollock; D J Stechschulte; G Wood
Journal:  Clin Immunol Immunopathol       Date:  1981-04

7.  Plasma exchange in systemic lupus erythematosus.

Authors:  H F Parry; C J Moran; M L Snaith; J D Richards; A H Goldstone; L J Nineham; F C Hay; W J Morrow; I M Roitt
Journal:  Ann Rheum Dis       Date:  1981-06       Impact factor: 19.103

8.  A sensitive solid phase microradioimmunoassay for anti-double stranded DNA antibodies.

Authors:  F Fish; M Ziff
Journal:  Arthritis Rheum       Date:  1981-03

9.  Immunologic dynamics in cryapheresis for rheumatoid arthritis.

Authors:  D J Wallace; E V Barnett; S Nichols; W Hancock; G Vibert; J Curd; J R Klinenberg; D Goldfinger
Journal:  J Rheumatol       Date:  1983-12       Impact factor: 4.666

10.  Specificity of anti-nucleoside antibodies in systemic lupus erythematosus.

Authors:  R H Weisbart; R A Garrett; M R Liebling; E V Barnett; H E Paulus; D H Katz
Journal:  Clin Immunol Immunopathol       Date:  1983-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.